Literature DB >> 27826620

Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET).

Kaizhou Jin1, Jin Xu1, Jie Chen2, Minhu Chen2, Rufu Chen3, Ye Chen4, Zhiyu Chen5, Bin Cheng6, Yihebali Chi7, Shi-Ting Feng8, Deliang Fu9, Baohua Hou10, Dan Huang11, Heguang Huang12, Qiang Huang13, Jie Li14, Ying Li15, Houjie Liang16, Rong Lin17, An'an Liu18, Jixi Liu19, Xubao Liu20, Ming Lu14, Jie Luo21, Gang Mai22, Quanxing Ni1, Meng Qiu23, Chenghao Shao18, Baiyong Shen24, Weiqi Sheng11, Jian Sun3, Chunlu Tan20, Huangying Tan25, Qiyun Tang26, Yingmei Tang27, Xiaodong Tian28, Danian Tong29, Xiaohong Wang30, Jian Wang31, Jie Wang32, Wei Wang34, Wei Wang34, Yu Wang35, Zheng Wu36, Ling Xue37, Qiang Yan38, Ning Yang39, Yinmo Yang28, Zhiying Yang40, Xiaoyi Yin41, Chunhui Yuan42, Shan Zeng43, Renchao Zhang44, Xianjun Yu45.   

Abstract

Pancreatic neuroendocrine neoplasms (p-NENs) are slowly growing tumors with frequent liver metastasis. There is a variety of approaches to treat non-functional p-NENs with synchronous liver metastasis (LM) which complicates the determination of optimal treatment. Based on updated literature review, we discussed the treatment strategy determinants for p-NEN with LM. According to the resectability of primary tumor, the WHO 2010 grade classification and the radiological type of liver metastasis, the CSNET group reached agreements on a number of issues, including the following. Prior to treatment, biopsy is required to confirm pathology. Liver biopsy is important for more accurate grading of tumor and percutaneous core needle biopsy is more available than EUS-FNA. In patients with unresectable primary, surgical resection for liver-metastatic lesions should be avoided. Curative surgery is recommended for G1/G2 p-NET with type I LM and R1 resection also seems to improve overall survival rate. Cytoreductive surgery is recommended for G1/G2 p-NET with type II LM in select patients, and should meet stated requirements. Surgical resection for G1/G2 p-NET with type III LM and p-NEC with LM should be avoided, and insufficient evidence exists to guide the surgical treatment of G3 p-NET with LM. Liver transplantation may be an option in highly select patients. In addition, the optimal time for surgical approach is still required for more evidence.

Entities:  

Mesh:

Year:  2016        PMID: 27826620     DOI: 10.3892/ijo.2016.3711

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  16 in total

Review 1.  Liver metastases.

Authors:  Diamantis I Tsilimigras; Pnina Brodt; Pierre-Alain Clavien; Ruth J Muschel; Michael I D'Angelica; Itaru Endo; Rowan W Parks; Majella Doyle; Eduardo de Santibañes; Timothy M Pawlik
Journal:  Nat Rev Dis Primers       Date:  2021-04-15       Impact factor: 52.329

2.  Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors.

Authors:  Guopei Luo; Kaizhou Jin; He Cheng; Chen Liu; Meng Guo; Yu Lu; Chao Yang; Jinzhi Xu; Wenquan Wang; Heli Gao; Shirong Zhang; Jiang Long; Jin Xu; Quanxing Ni; Jie Chen; Xianjun Yu
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

Review 3.  Pancreatic neuroendocrine tumors.

Authors:  Jian Sun
Journal:  Intractable Rare Dis Res       Date:  2017-02

Review 4.  Neuroendocrine liver metastases: a contemporary review of treatment strategies.

Authors:  Jordan M Cloyd; Aslam Ejaz; Bhavana Konda; Mina S Makary; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

5.  Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.

Authors:  Shinsei Yumoto; Shigeki Nakagawa; Hiromitsu Hayashi; Daisuke Ogawa; Yuta Shiraishi; Hiroki Sato; Takashi Matsumoto; Katsunori Imai; Yo-Ichi Yamashita; Hideo Baba
Journal:  Clin J Gastroenterol       Date:  2022-08-29

6.  Value of computed tomography evaluation in pathologic classification and prognosis prediction of gastric neuroendocrine tumors.

Authors:  Shida Yan; Tongtong Liu; Ying Li; Yongjian Zhu; Jun Jiang; Liming Jiang; Hong Zhao
Journal:  Ann Transl Med       Date:  2019-10

7.  Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases.

Authors:  Si Shi; Xian-Jun Yu
Journal:  World J Gastroenterol       Date:  2018-09-07       Impact factor: 5.742

8.  Worth it or not? Primary tumor resection for stage IV pancreatic cancer patients: A SEER-based analysis of 15,836 cases.

Authors:  Ningzhen Fu; Yu Jiang; Yuanchi Weng; Hao Chen; Xiaxing Deng; Baiyong Shen
Journal:  Cancer Med       Date:  2021-07-21       Impact factor: 4.452

9.  A modified M-stage classification based on the metastatic patterns of pancreatic neuroendocrine neoplasms: a population-based study.

Authors:  Xianbin Zhang; Jiaxin Song; Peng Liu; Mohammad Abdul Mazid; Lili Lu; Yuru Shang; Yushan Wei; Peng Gong; Li Ma
Journal:  BMC Endocr Disord       Date:  2018-10-19       Impact factor: 2.763

10.  Treatment options for PNET liver metastases: a systematic review.

Authors:  Giuseppe Nigri; Niccolò Petrucciani; Tarek Debs; Livia Maria Mangogna; Anna Crovetto; Giovanni Moschetta; Raffaello Persechino; Paolo Aurello; Giovanni Ramacciato
Journal:  World J Surg Oncol       Date:  2018-07-14       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.